Jul 19 2007
Starpharma Holdings Limited today announced that it has signed an agreement with a leading condom company in relation to the use of VivaGel™ as a condom coating.
The agreement includes a program of evaluation and development and also commercialisation rights covering condoms with VivaGel™ coatings within a specified geographical region. The condom company, whose name may not be disclosed for reasons of confidentiality, holds the leading market position within that region. The market in question is in the developed world, and ranks within the top five globally, measured by GDP.
The terms of the agreement were not disclosed.
"We are pleased to be able to report this solid progress in the commercialisation of VivaGel™ as a condom coating," commented Starpharma CEO, Dr Jackie Fairley. "This announcement reflects some of the growing momentum that we are achieving as we work to bring VivaGel™ as a condom coating to market."
VivaGel™ is in development as a vaginal microbicide, to prevent infection with HIV or genital herpes, under two FDA INDs*. It has also been shown to have a potent contraceptive effect in animals. Its development as a condom coating represents a line extension to the standalone, applicator delivered vaginal microbicide.